# Attitudes to Drug Policy in Australia, 2001-2022/23: What Does This Mean for Drug Policy Reform in Australia? > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/australian-national-drug-strategy-household-survey-insights/ > **Published:** 2026-03-24T16:15:17-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:40:42-04:00 > **Clinical Summary:** Explore findings from the Australian National Drug Strategy Household Survey on public attitudes toward drug policy and harm reduction services. --- CED Clinical Relevance  #50Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic [Harm Reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/)Public Policy[Addiction Medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/)NaloxoneClinical Advocacy Journal Drug and alcohol review Study Type [Clinical Study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) Population Human participants Why This Matters Understanding public attitudes toward drug policy directly impacts clinical access to evidence-based interventions like needle exchange programs and supervised injection facilities. This data reveals where clinical advocacy efforts may be most needed to ensure patients can access proven [harm reduction](https://cedclinic.com/can-you-mix-weed-and-alcohol/) services. Clinical Summary This analysis of Australian National Drug Strategy Household Survey data from 2001-2022/23 examined public attitudes toward various drug policies and harm reduction interventions. The study found majority public support for evidence-based harm reduction services including needle and syringe programs (67.8%), supervised injection facilities (58.3%), naloxone distribution (60.9%), and drug checking services (64.4%). However, strong opposition remained for drug legalization, with 86.6% opposing methamphetamine legalization and 75.8% opposing ecstasy legalization. The study also analyzed media coverage trends of these policies over the two-decade period. Dr. Caplan’s Take “This data confirms what I see clinically – patients often struggle to access basic harm reduction services despite evidence supporting their efficacy and growing public acceptance. The disconnect between support for harm reduction and opposition to legalization reflects the nuanced policy landscape clinicians must navigate.” Clinical Perspective 🧠 Clinicians should feel encouraged that public opinion increasingly supports evidence-based harm reduction interventions they recommend. However, continued [patient education](https://cedclinic.com/medical-cannabis-patient-education-basics/) and advocacy remain essential, particularly in jurisdictions where policy implementation lags behind public acceptance. Understanding these attitude trends can help clinicians frame discussions about harm reduction with patients and communities. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Attitudes%20to%20Drug%20Policy%20in%20Australia%2C%202001-2022/23%3A%20What%20Does%20This%20Mean%20for%20Dru...%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41832941/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41832941/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Attitudes%20to%20Drug%20Policy%20in%20Australia%2C%202001-2022/23%3A%20What%20Does%20This%20Mean%20for%20Dru...%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41832941/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41832941/](https://pubmed.ncbi.nlm.nih.gov/41832941/) Table of Contents - [FAQ](#FAQ)[What harm reduction services do Australians currently support?](#What_harm_reduction_services_do_Australians_currently_support) - [Should I recommend take-home naloxone to patients at risk of opioid overdose?](#Should_I_recommend_take-home_naloxone_to_patients_at_risk_of_opioid_overdose) - [How should clinicians approach conversations about drug policy with patients?](#How_should_clinicians_approach_conversations_about_drug_policy_with_patients) - [What does this mean for referring patients to supervised injecting facilities?](#What_does_this_mean_for_referring_patients_to_supervised_injecting_facilities) - [How can clinicians advocate for drug policy reform based on this evidence?](#How_can_clinicians_advocate_for_drug_policy_reform_based_on_this_evidence) - [Related](#Related) ## FAQ #### What harm reduction services do Australians currently support? According to 2022/23 data, Australians show strong support for evidence-based harm reduction interventions. Support includes needle and syringe programs (67.8%), supervised injecting facilities (58.3%), take-home naloxone programs (60.9%), and drug checking services (64.4%). #### Should I recommend take-home naloxone to patients at risk of opioid overdose? Yes, with 60.9% public support and strong clinical evidence, take-home naloxone is well-accepted in Australia. This survey data supports clinical recommendations for naloxone distribution to patients using opioids and their contacts as a life-saving intervention. #### How should clinicians approach conversations about drug policy with patients? Clinicians can leverage the documented public support for harm reduction services when discussing treatment options with patients. Understanding that most Australians support evidence-based interventions can help reduce stigma and encourage patient engagement with these services. #### What does this mean for referring patients to supervised injecting facilities? With 58.3% public support, supervised injecting facilities have gained acceptance as legitimate healthcare interventions. Clinicians can confidently refer appropriate patients to these facilities, knowing they operate within a supportive policy environment in jurisdictions where available. #### How can clinicians advocate for drug policy reform based on this evidence? This data provides clinicians with evidence-based talking points showing majority public support for harm reduction services. Clinicians can use these statistics when engaging with policymakers, emphasizing that evidence-based drug policies align with both clinical best practice and community acceptance. {“@context”: “https://schema.org”, “@type”: “ScholarlyArticle”, “headline”: “Attitudes to Drug Policy in Australia, 2001-2022/23: What Does This Mean for Drug Policy Reform in Australia?”, “url”: “https://pubmed.ncbi.nlm.nih.gov/41832941/”, “about”: “drug alcohol review [clinical study](https://cedclinic.com/cannabis-hyperemesis-syndrome-psychiatric-risk/) attitudes”, “isPartOf”: “Drug and alcohol review”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [A mixed-methods evaluation of a statewide naloxone distribution project](https://cedclinic.com/opioid-overdose-prevention-naloxone-distribution-evaluation/) Explore considerations for future opioid overdose prevention initiatives based on a comprehensive naloxone distribution project evaluation. [Read More](https://cedclinic.com/opioid-overdose-prevention-naloxone-distribution-evaluation/) [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) Review clinical insights on the complex interactions between opioids and [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and their implications for treatment. [Learn More](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) [Substance Use and Suicide Attempts in Adolescents](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/) A comparative analysis of clinical and psychosocial risk factors related to adolescent substance use and suicide attempts. [Explore Study](https://cedclinic.com/adolescent-substance-use-suicide-risk-analysis/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).